Arrhythmias & electrophysiology
Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC)
Primary result · Median PVC burdenResult — go to the resultReduction in median PVC burden 13.4%Authors' conclusion
LLTS effectively reduced PVC burden in patients with symptomatic PVCs refractory to medical therapy, highlighting its potential as an adjuvant therapeutic option. Larger, multicenter trials are warranted to confirm these findings and evaluate long-term outcomes [Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes (NoVa-PVC); NCT05341544].
Study context
- Population
- Patients with symptomatic premature ventricular complexes (PVCs) with at least 5% daily PVC burden and who were refractory to medical therapycompleted the study and were included in the analysis, of 36 randomized patients
- Participants
- 35 patients
- Comparison
- active LLTS vs sham stimulation, crossover with 8-day washout
Methodological details2-center
- 2-center
Primary result
Median PVC burden
Reduction in median PVC burden
13.4%
P = 0.021
As reported in the abstract
- Median PVC burden, as printed
- 10.5% [IQR: 14.4%] vs 8.59% [IQR: 8.45%]
Further findings
Heart rate variability
- No significant differences in heart rate variability between the 2 groups
Baseline PVC burden
- Median baseline PVC burden
- 12.00% (IQR: 11.4%)
Exploratory analyses
- More pronounced reduction in slow heart rate-dependent PVCs and a sustained decrease in PVC burden throughout the LLTS period
- Exploratory
Original publication
Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions: A Crossover, Randomized Clinical Trial (NoVa-PVC). JACC Clin Electrophysiol. Published 24 April 2025. doi:10.
Summarised from the published abstract; every number is checked against it